Biomarkers in Transplant Recipients to Improve Outcomes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Pittsburgh
About this trial
The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs that are used to treat rejection, and of processes leading to rejection and rejection-free outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center.
All Ages
Subject or parents are able to read and understand the informed consent
Disqualifiers
Subjects and/or their parents who are unable to read and understand informed consent.
Trial population
Individuals who are listed and or recipients of solid organ or bone marrow transplantation.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Rejection
Biopsy-proven acute cellular rejection
Time frame
90 day post transplantation (clinical severity)Secondary outcomes
1
Thresholds of immunosuppression
Blood levels and doses of the various immunosuppressants at one year. For example, Tacrolimus is measured as nanograms/ml in whole blood, Mycophenolate mofetil is measured in doses of mg/day, or as blood levels in micrograms/ml, steroids doses are measured in mg/day, Sirolimus is measured in doses of mg/day, or as blood levels in nanograms/ml in whole blood.
Time frame
Yearly post transplantationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov